EGFR and neoplasm: Consequently, we evaluated the efficiency of the suppression of all four variants of EGFR-TK receptors (Figures 9A, B), cell death induction in tumor cells (Figure 9C) and inhibition of tumor growth by the proposed NLC-based delivery system (Figure 9D).